Holen Sie sich die Stockscreener-App
4.54
2.58%
-0.12
Handel nachbörslich:
4.54
Schlusskurs vom Vortag:
$4.66
Offen:
$4.45
24-Stunden-Volumen:
278.69K
Relative Volume:
0.67
Marktkapitalisierung:
$205.29M
Einnahmen:
$84.82M
Nettoeinkommen (Verlust:
$-21.43M
KGV:
-9.2653
EPS:
-0.49
Netto-Cashflow:
$-27.23M
1W Leistung:
-5.61%
1M Leistung:
-8.47%
6M Leistung:
-67.94%
1J Leistung:
-68.82%
1-Tages-Spanne:
$4.30
$4.64
1-Wochen-Bereich:
$4.25
$4.815
52-Wochen-Spanne:
$4.25
$17.78
Y Mabs Therapeutics Inc Stock (YMAB) Company Profile
Firmenname
Y Mabs Therapeutics Inc
Sektor
Branche
Telefon
646-885-8505
Adresse
202 CARNEGIE CENTER, PRINCETON, NY
Vergleichen Sie YMAB mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
YMAB
Y Mabs Therapeutics Inc
|
4.54 | 205.29M | 84.82M | -21.43M | -27.23M | -0.49 |
|
VRTX
Vertex Pharmaceuticals Inc
|
474.62 | 121.88B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
573.45 | 62.69B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
555.11 | 33.86B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
235.74 | 30.51B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
238.51 | 25.69B | 3.81B | -644.79M | -669.77M | -6.24 |
Y Mabs Therapeutics Inc Stock (YMAB) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-11-18 | Eingeleitet | Oppenheimer | Outperform |
| 2024-08-16 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2024-06-28 | Eingeleitet | Truist | Buy |
| 2023-05-10 | Hochstufung | Wedbush | Neutral → Outperform |
| 2023-04-03 | Herabstufung | Guggenheim | Buy → Neutral |
| 2023-01-27 | Herabstufung | Morgan Stanley | Equal-Weight → Underweight |
| 2023-01-05 | Herabstufung | Cowen | Outperform → Market Perform |
| 2022-12-02 | Herabstufung | BofA Securities | Buy → Neutral |
| 2022-10-31 | Herabstufung | JP Morgan | Neutral → Underweight |
| 2022-10-31 | Herabstufung | Wedbush | Outperform → Neutral |
| 2022-07-06 | Fortgesetzt | Canaccord Genuity | Buy |
| 2022-06-24 | Eingeleitet | BMO Capital Markets | Outperform |
| 2022-02-03 | Fortgesetzt | Guggenheim | Buy |
| 2021-11-19 | Fortgesetzt | Morgan Stanley | Equal-Weight |
| 2021-11-16 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2021-05-07 | Hochstufung | BofA Securities | Neutral → Buy |
| 2021-04-23 | Fortgesetzt | Cowen | Outperform |
| 2021-03-22 | Fortgesetzt | JP Morgan | Overweight |
| 2021-01-15 | Herabstufung | BofA Securities | Buy → Neutral |
| 2020-11-09 | Bestätigt | H.C. Wainwright | Buy |
| 2020-05-05 | Eingeleitet | Barclays | Overweight |
| 2020-05-01 | Eingeleitet | Janney | Buy |
| 2020-04-29 | Eingeleitet | Morgan Stanley | Equal-Weight |
| 2019-12-24 | Eingeleitet | JP Morgan | Overweight |
| 2019-11-20 | Eingeleitet | Guggenheim | Buy |
| 2019-09-04 | Eingeleitet | Wedbush | Outperform |
| 2019-04-01 | Eingeleitet | H.C. Wainwright | Buy |
| 2018-10-16 | Eingeleitet | BTIG Research | Buy |
| 2018-10-16 | Eingeleitet | BofA/Merrill | Buy |
Alle ansehen
Y Mabs Therapeutics Inc Aktie (YMAB) Neueste Nachrichten
Y-mAbs Therapeutics, Inc.'s (NASDAQ:YMAB) latest 12% decline adds to one-year losses, institutional investors may consider drastic measures - simplywall.st
Refractory Metastatic Melanoma Clinical and Non-Clinical - openPR.com
Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Stake Boosted by Charles Schwab Investment Management Inc. - Defense World
Top Premarket Decliners - MarketScreener
Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Given Average Rating of “Moderate Buy” by Brokerages - Defense World
HC Wainwright Has Lowered Expectations for Y-mAbs Therapeutics (NASDAQ:YMAB) Stock Price - Defense World
Breaking Down Y-mAbs Therapeutics: 5 Analysts Share Their Views - Benzinga
Learn to Evaluate (YMAB) using the Charts - news.stocktradersdaily.com
12 Health Care Stocks Moving In Thursday's Pre-Market Session - Benzinga
Y-mabs therapeutics CBO Gad Thomas sells $56,536 in stock - Investing.com India
Y-mabs therapeutics CEO Michael Rossi sells $20,368 in stock By Investing.com - Investing.com South Africa
Y-mabs therapeutics CBO Gad Thomas sells $56,536 in stock By Investing.com - Investing.com Australia
Y-mabs therapeutics CEO Michael Rossi sells $20,368 in stock - Investing.com
Y-mAbs Therapeutics Executives Sell Shares - TradingView
Y-mAbs Therapeutics, Inc. (YMAB) Reports Q4 Loss, Lags Revenue Estimates - MSN
YMAB Q1 EPS Estimate Boosted by Brookline Capital Management - MarketBeat
Bearish: Analysts Just Cut Their Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Revenue and EPS estimates - Yahoo
FY2025 EPS Estimates for YMAB Reduced by Cantor Fitzgerald - Defense World
Wedbush Reduces Earnings Estimates for Y-mAbs Therapeutics - Defense World
Brookline Capital Management Predicts YMAB Q1 Earnings - Defense World
From Clinical Trials to the Market: Cancer Stocks With Big Potential in 2025 - Baystreet.ca
Y-mAbs Therapeutics, Inc. to Host Earnings Call - ACCESS Newswire
Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Just Reported And Analysts Have Been Cutting Their Estimates - Simply Wall St
Truist Financial Has Lowered Expectations for Y-mAbs Therapeutics (NASDAQ:YMAB) Stock Price - Defense World
Bank of America Lowers Y-mAbs Therapeutics (NASDAQ:YMAB) Price Target to $12.00 - Defense World
Morgan Stanley Issues Pessimistic Forecast for Y-mAbs Therapeutics (NASDAQ:YMAB) Stock Price - Defense World
Forecasting The Future: 4 Analyst Projections For Y-mAbs Therapeutics - Benzinga
Y-mAbs Therapeutics price target lowered to $12 from $14 at BofA - TipRanks
Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Q4 2024 Earnings Call Transcript - Insider Monkey
Oppenheimer Adjusts Y-mAbs Therapeutics Price Target to $21 From $23, Maintains Outperform Rating - Marketscreener.com
Truist Cuts Price Target on Y-mAbs Therapeutics to $18 From $21, Keeps Buy Rating -March 05, 2025 at 06:27 am EST - Marketscreener.com
Y-mAbs Therapeutics Inc (YMAB) Q4 2024 Earnings Call Highlights: Strategic Realignment and ... By GuruFocus - Investing.com Canada
Y-mAbs Therapeutics Reports 2024 Financial Results - TipRanks
Y-mAbs Therapeutics’ Earnings Call Highlights Mixed Results - TipRanks
Y-mAbs Therapeutics inks equity deal up to $35M - Investing.com India
Y-mAbs Therapeutics Inc Enters Equity Distribution Agreement With Oppenheimer -March 04, 2025 at 04:32 pm EST - Marketscreener.com
Y-mAbs Therapeutics inks equity deal up to $35M By Investing.com - Investing.com UK
SEC Form 424B5 filed by Y-mAbs Therapeutics Inc. - Quantisnow
Y-mAbs stock price target cut to $19 at Cantor Fitzgerald - Investing.com UK
Wedbush Cuts Price Target on Y-mAbs Therapeutics to $21 From $23, Keeps Outperform Rating - Marketscreener.com
Y-mAbs Therapeutics Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Y-mAbs Therapeutics (NASDAQ:YMAB) shareholders have endured a 79% loss from investing in the stock five years ago - Yahoo Finance
Y-mAbs announces publication of Phase 2 interim results on naxitamab - Yahoo Finance
Y-mAbs Therapeutics Reports Fourth Quarter 2024 Financial Results - TradingView
Y-mAbs Reports Fourth Quarter 2024 Financial Results -March 04, 2025 at 07:06 am EST - Marketscreener.com
Y-mAbs Reports Fourth Quarter 2024 Financial Results and Recent Corporate Developments - The Manila Times
Y-mAbs Therapeutics reports Q4 EPS (15c), consensus (13c) - TipRanks
Y-mAbs Therapeutics (NASDAQ:YMAB) Given “Outperform” Rating at Wedbush - Defense World
Leptomeningeal Metastases Market Anticipated to Expand - openPR
Naxitamab shows promise in neuroblastoma phase 2 trial - Investing.com
Y-mAbs Announces Publication of Phase 2 Interim Results in Nature Communications - The Manila Times
Finanzdaten der Y Mabs Therapeutics Inc-Aktie (YMAB)
Umsatz
Nettogewinn
Free Cashflow
ENV
3.01%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):